Pre-market
Loading markets…

Advertisement

Stocks

Why Briacell Therapeutics Corp stock surged yesterday

By Wealth Awesome -

This move is archived. Current quotes and coverage live on the stock page.

Stocks & ETFs:BCT.TO

Follow BCT

Photos provided by Pexels

Briacell Therapeutics Corp saw a notable uptick in its stock price, reflecting investor confidence.

Briacell Therapeutics Corp (BCT.TO) experienced a significant surge in its stock price yesterday, closing up by 12.37% to CA$5.45. This positive movement can be attributed to a combination of favorable market sentiment and recent developments surrounding the company's innovative cancer therapies.

Advertisement

Briacell Therapeutics Corp

BCT.TO

Full stock page →

BCT.TO

Briacell Therapeutics Corp

Source:WealthAwesomeWealthAwesome
↓ $0.21 (-3.55%)
120 day period
$3.80$4.95$6.10Apr 16Jul 13Oct 6

Market cap

$51.59M

52W high

$20.40

52W low

$3.68

1W change

-1.72%

Beta

1.51

Analyst Price Targets

Based on analyst covering BCT · as of Sep 17, 2026

📈

Wall Street analysts forecast BCT stock price to rise 250.9% over the next 12 months.

Consensus

Bullish

Based on avg. target vs last close (formal rating unavailable for Canadian listings)

Avg. Target

C$20.00

+250.9% Upside

Current Price

C$5.70

Last close

Compare analyst targets →

Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on BCT's historical volatility

HistoricalForecast68%95%
C$2.27C$4.86C$7.45C$10.04C$12.63C$15.21TodayMay 29Aug 4Oct 6Nov 18Jan 1Feb 13

30-Day Vol

77.0%

Annualized

90-Day Vol

71.7%

Annualized

Trend (90d)

+8.9%

Annualized drift

90d Mean

C$5.88

Expected price

HorizonExpected68% Range (1σ)
30 trading daysC$5.76C$4.42 – C$7.51
60 trading daysC$5.82C$4.00 – C$8.48
90 trading daysC$5.88C$3.71 – C$9.32

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

Advertisement

Investor takeaway: Investors should monitor Briacell's ongoing advancements in immunotherapy, as they may continue to drive stock performance.

Briacell's stock surged by 12.37% yesterday

The market cap of Briacell Therapeutics Corp is currently CA$47.4 million, reflecting its potential growth in the biotech sector.

Bull case

The recent announcement of a complete resolution of lung metastasis in a patient treated with Bria-OTS™ highlights the effectiveness of Briacell's therapies. This promising result could attract more investment and interest in the company's future.

Bear case

Despite the positive surge, investors should stay cautious. The company has not yet established consistent profitability, and market volatility could affect future performance.

Advertisement

Recent Developments Fueling Growth

Briacell's recent announcements, including the positive outcomes of its Bria-OTS™ treatment, have generated significant interest among investors. The complete resolution of lung metastasis in a patient with metastatic breast cancer shows the potential of their personalized immunotherapy. This news likely contributed to the stock's impressive performance yesterday, as investors reacted positively to the company's advancements in cancer treatment.

Market Response and Future Outlook

The surge in Briacell's stock price reflects growing confidence in the biotech sector, especially in companies focused on innovative therapies. However, investors should remain vigilant. While the recent gains are promising, the company's lack of profitability and the inherent risks in the biotech industry could pose challenges ahead. Keeping an eye on upcoming clinical trial results and market trends will be crucial for assessing Briacell's future performance. For more insights, check out our detailed analysis on Briacell Therapeutics Corp.


Advertisement

Wealth Awesome
Written by

Wealth Awesome

Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.

View Full Profile →

✅ Reviewed by Certified Financial Professionals

This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.

Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.

📊 Data AccuracyVerified sources
🇨🇦 Canadian FocusLocal expertise
🔍 Fact-CheckedEditorial review

⚠️ Professional Disclaimer

This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.

Published: August 20, 2026
Last Updated: October 1, 2026

Core portfolio

Awesome Portfolio™

14.8% a year since 2017, against 9.7% for the S&P/TSX Composite. Ten stocks, easy to manage. We update it once a month.

Annualized

+14.8%

Awesome Portfolio™

+9.7%

S&P/TSX

+5.0 pp better a year

Total return

+254%

Awesome Portfolio™

+134%

S&P/TSX

+119 pp better than the TSX

2017-07-31 to 2026-09-29, dividends reinvested, before fees and tax.

Awesome Portfolio™S&P/TSX CompositeCumulative return · 2017-07-31–2026-09-29
-11.7%42.5%96.7%150.9%205.1%259.3%Jul 17Oct 19Feb 22Jun 24Sep 26

Sponsored links

Advertisement